|
Commitments and Contingencies (Details Textual)
|
6 Months Ended | 3 Months Ended | 6 Months Ended | 1 Months Ended | 6 Months Ended | |||||
|---|---|---|---|---|---|---|---|---|---|---|
|
Jun. 30, 2013
USD ($)
|
Dec. 31, 2012
USD ($)
|
Jun. 30, 2013
Vancouver Canada and Bothell Washington offices [Member]
USD ($)
|
Jun. 30, 2012
Vancouver Canada and Bothell Washington offices [Member]
USD ($)
|
Jun. 30, 2013
Vancouver Canada and Bothell Washington offices [Member]
USD ($)
|
Jun. 30, 2012
Vancouver Canada and Bothell Washington offices [Member]
USD ($)
|
Dec. 31, 2009
TEVA Pharmaceutical Industries Ltd. [Member]
USD ($)
|
Jun. 30, 2013
TEVA Pharmaceutical Industries Ltd. [Member]
USD ($)
|
Jun. 30, 2013
Isis Pharmaceuticals Inc. and University of British Columbia [Member]
USD ($)
|
Jun. 30, 2013
Isis Pharmaceuticals Inc. and University of British Columbia [Member]
CAD
|
|
| Commitments And Contingencies (Additional Textual) [Abstract] | ||||||||||
| Collaboration agreement aggregate amount | $ 50,000,000 | |||||||||
| Maximum amount receivable | 370,000,000 | |||||||||
| Equity investment | 15,000 | 15,000 | 10,000,000 | |||||||
| Direct and indirect development costs | 30,000,000 | |||||||||
| Milestone payment due | 20,000,000 | |||||||||
| Period of milestone payment | 21 days | 21 days | ||||||||
| Amount receivable by Isis from TEVA as a milestone payment | 30.00% | 30.00% | ||||||||
| Reserve for contingency of non payment of non-royalty milestone amount | 20,000,000 | |||||||||
| Milestone payment made | 10,000,000 | |||||||||
| Balance amount of milestone payment | 10,000,000 | |||||||||
| Percentage of un-spent portion to be paid | 30.00% | 30.00% | ||||||||
| Proceeds from introduction of new agreement | 800,000 | 100,000 | ||||||||
| Obligation to pay patent costs and license maintenance fees | 8,000 | |||||||||
| Expiry period of agreement of patented license | 20 years | 20 years | ||||||||
| Milestone payment | 7,750,000 | 1,600,000 | ||||||||
| Other assets | 500,000 | 500,000 | ||||||||
| Consolidated rent expense | 700,000 | 700,000 | 1,400,000 | 1,300,000 | ||||||
| Letter of credit | 300,000 | 300,000 | ||||||||
| Lease liability | 4,300,000 | |||||||||
| Commitments and Contingencies (Textual) [Abstract] | ||||||||||
| Direct and indirect cost incurred by OncoGenex | $ 30,000,000 | |||||||||
| Range of each product line | 10 years | |||||||||
| Expiration of operating lease agreement | 2014-09 | |||||||||
| Expiration of non cancellable operating lease agreement | 2017 | |||||||||